World Health Organization (WHO) announced in late February the recommended seasonal influenza virus strains for use in the Northern hemisphere. The recommendation includes two strains of influenza A viruses, H1N1 and H3N2, and two strains of influenza B viruses, Victoria and Yamagata. Vaccine manufacturers around the world will initiate their influenza vaccine production accordingly. Adimmune Corporation (4142) precisely predicted the strains this year and has already finished subculturing; the company is ready to manufacture influenza vaccines to meet the domestic and overseas demand.
C. C. Chang, COO of Adimmune, said that although Taiwan is not a member of WHO, Adimmune has joined International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to access the global surveillance data of influenza virus from WHO as well as to exchange vaccine information with international biopharmaceutical companies. As of now, IFPMA has 21 members worldwide, including vaccine manufacturers such as Sanofi and GSK, while Adimmune is the only one from Taiwan.
In response to the COVID-19 pandemic, this year, WHO announced the recommended seasonal influenza virus strains via a video conference from 20:00 to 24:00 on February 26, Taiwan time. Adimmune participated in the entire event to acquire the first-hand updates. C. C. Chang said that WHO conducts development of high-yield strains in UK, Australia, USA, Japan, and China every year for the recommended seasonal influenza virus strains. WHO will announce the recommended seasonal influenza virus strains each year in February and September for use in the Northern hemisphere and in the Southern hemisphere respectively.
The WHO announcement of the recommended seasonal influenza virus strains is a major event for the vaccine manufacturers around the world. Each year, the companies, anticipating the announcement, try to predict the composition to ready themselves for an early production. Experienced in seasonal influenza virus prediction and vaccine manufacture, Adimmune precisely predicted two strains of the Influenza A viruses and two strains of Influenza B viruses. The company has prepared the specific pathogen free (SPF) eggs, conducted subculture, and selected the high-yield virus strains. It is already in the antigen manufacturing stage and is confident in managing the manufacture schedule this year to supply the demand of influenza vaccines at home and abroad.